CIC
NAGE

Chase Investment Counsel’s Niagen Bioscience NAGE Stock Holding History

Chase Investment Counsel’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,246
Closed -$349K – 160
2025
Q2 		$349K Buy
+24,246
New +$239K 0.11% 112

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Chase Investment Counsel's NAGE Position: Q3 2025 in Review

Chase Investment Counsel sold out of Niagen Bioscience (NAGE) in Q3 2025, closing a stake of 24,246 shares — an estimated $349K sold.

Chase Investment Counsel first reported a position in NAGE in Q2 2025 and held it in 1 quarter. The position peaked at $349K in Q2 2025. 162 funds tracked by Wall St. Rank hold NAGE as of Q3 2025.

  • Chase Investment Counsel reported no remaining Niagen Bioscience position as of Q3 2025 after selling out during the quarter.
  • Chase Investment Counsel sold 24,246 Niagen Bioscience shares in Q3 2025, an estimated $349K.
  • Chase Investment Counsel first reported a position in Niagen Bioscience in Q2 2025 and held it in 1 quarter.
  • Chase Investment Counsel's Niagen Bioscience position peaked at $349K in Q2 2025.
  • 162 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2025.

Based on Chase Investment Counsel's 13F filing for Q3 2025, filed 10 Nov 2025.